Skip to content
All Sections
Subscribe Now
92°F
Tuesday, August 27th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
92°F
Tuesday, August 27th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Legend Biotech
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
June 03, 2024
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
June 02, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Appointment of Chief Medical Officer
April 11, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
June 05, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Establishes Strategic Advisory Board
April 03, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
March 30, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
February 24, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
February 21, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
January 27, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC
January 09, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
January 03, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
January 02, 2023
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
November 21, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
November 04, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
August 19, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
August 04, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
June 04, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
June 03, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
June 01, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 26, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
May 18, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
May 09, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Participation in Upcoming Investor Conferences
May 06, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T
April 21, 2022
From
Legend Biotech
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
March 25, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
March 23, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 18, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
February 18, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
February 15, 2022
From
Legend Biotech
Via
Business Wire
Tickers
LEGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close